Related Experiment Videos
Prostate cancer: endogenous chemical castration
Olugbemisola Oredein McCoy1, Michaella M Prasad1, Natalie Singer2
1Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA.
BMJ Case Reports
|April 30, 2016
Summary
A pituitary adenoma caused temporary androgen deprivation in an intermediate-risk prostate cancer patient. Treatment led to undetectable prostate-specific antigen (PSA) levels, demonstrating successful management of both conditions.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Intermediate-risk prostate cancer diagnosis requires effective treatment strategies.
- Pituitary adenomas can cause hormonal imbalances, including hypogonadism.
- Prostate-specific antigen (PSA) monitoring is crucial for prostate cancer management.
Observation:
- A patient with intermediate-risk prostate cancer presented with elevated PSA.
- The patient developed hypogonadism and visual disturbances due to a pituitary adenoma.
- The pituitary adenoma led to a temporary period of androgen deprivation.
Findings:
- Surgical resection of the pituitary tumor normalized hormone levels.
- The patient completed radiation therapy for prostate cancer.
- Prostate-specific antigen (PSA) levels reached undetectable levels post-treatment.
Implications:
- This case highlights the successful management of prostate cancer despite concurrent endocrine disruption.
- It demonstrates the importance of investigating hormonal changes in cancer patients.
- Effective treatment of the pituitary adenoma allowed for successful prostate cancer therapy.